On February 3, 2014 OncoTherapy Science reported that the patient enrollment in the Phase II clinical study of cancer peptide vaccine S-588410, which contains five oncoantigen peptides and outlicensed to Shionogi&Co., Ltd, in bladder cancer patients has been commenced in Japan and Europe, as released by Shionogi today (Press release OncoTherapy Science, FEB 3, 2014, View Source [SID:1234500732]). This clinical study is to evaluate the clinical effect of S-588410 when administered to the bladder cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

S-588410 is a mixed peptide cocktail vaccine of S-288310, for which Shionogi has already conducted a clinical study, and S-488310 (BSG NOTE: Possibly S-488410?), and is expected to have an advanced efficacy.

OncoTherapy has decided to leave fiscal 2013 full-year forecasts announced on 31th January,2014 unchanged.